Low molecular weight heparin dosing regimens after total joint arthroplasty: a prospective, single-center, randomized, double-blind study.

ABSTRACT:

Background

Low molecular weight heparin (LMWH) has been the standard treatment for preventing venous thromboembolism after total joint arthroplasty. However, the evidence supporting specific LMWH dosing regimens is limited.

Objectives

This study assessed the efficacy and safety of three enoxaparin dosing regimens to prevent venous thromboembolism.

Methods

Participants undergoing hip or knee replacement were randomly assigned to receive 20 mg of enoxaparin 6 h postoperatively (Group A), 40 mg 6 h postoperatively (Group B), or 40 mg 12 h postoperatively (Group C). The primary outcomes included thromboembolic and major bleeding events within 3 months, while the secondary outcomes comprised ecchymosis, wound exudation, drainage volume, allogeneic red blood cell transfusio

SUBMITTER: Shang J 

PROVIDER: S-EPMC11600787 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature